Cargando…
p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083709/ https://www.ncbi.nlm.nih.gov/pubmed/25028664 http://dx.doi.org/10.1155/2014/717919 |
_version_ | 1782324411223769088 |
---|---|
author | Teoh, P. J. Chng, W. J. |
author_facet | Teoh, P. J. Chng, W. J. |
author_sort | Teoh, P. J. |
collection | PubMed |
description | p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials. This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic. Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma. |
format | Online Article Text |
id | pubmed-4083709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40837092014-07-15 p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma Teoh, P. J. Chng, W. J. Biomed Res Int Review Article p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials. This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic. Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma. Hindawi Publishing Corporation 2014 2014-06-17 /pmc/articles/PMC4083709/ /pubmed/25028664 http://dx.doi.org/10.1155/2014/717919 Text en Copyright © 2014 P. J. Teoh and W. J. Chng. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Teoh, P. J. Chng, W. J. p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma |
title | p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma |
title_full | p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma |
title_fullStr | p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma |
title_full_unstemmed | p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma |
title_short | p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma |
title_sort | p53 abnormalities and potential therapeutic targeting in multiple myeloma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083709/ https://www.ncbi.nlm.nih.gov/pubmed/25028664 http://dx.doi.org/10.1155/2014/717919 |
work_keys_str_mv | AT teohpj p53abnormalitiesandpotentialtherapeutictargetinginmultiplemyeloma AT chngwj p53abnormalitiesandpotentialtherapeutictargetinginmultiplemyeloma |